Available anti-malarial tools have over the ten-year period prior to 2012 dramatically reduced the number of fatalities due to malaria from one million to less than six-hundred and thirty thousand. Although fewer people now die from malaria, emerging resistance to the first-line anti-malarial drugs, namely artemisinins in combination with quinolines and arylmethanols, necessitates the urgent development of new anti-malarial drugs to curb the disease. The quinolones are a promising class of compounds, with some demonstrating potent in vitro activity against the malaria parasite. This review summarizes the progress made in the development of potential anti-malarial quinolones since 2008. The efficacy of these compounds against both asexual blood stages and other stages of the malaria parasite, the nature of putative targets, and a comparison of these properties with anti-malarial drugs currently in clinical use, are discussed.
CITATION STYLE
Beteck, R. M., Smit, F. J., Haynes, R. K., & N’Da, D. D. (2014, August 30). Recent progress in the development of anti-malarial quinolones. Malaria Journal. BioMed Central Ltd. https://doi.org/10.1186/1475-2875-13-339
Mendeley helps you to discover research relevant for your work.